Raising cellular O-GlcNAc levels with OGA inhibitors (NButGT, TMG, and PUGNAc) in the AD-susceptible 5XFAD mice and tau/APP mice enhanced cognitive performance, reduced Aβ peptide levels, and suppressed amyloid plaque deposition [181,182]. This evidence concerns the gene MAPT and Alzheimer disease.